1. Home
  2. JYNT vs SCLX Comparison

JYNT vs SCLX Comparison

Compare JYNT & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.79

Market Cap

149.5M

Sector

Miscellaneous

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$14.08

Market Cap

139.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
SCLX
Founded
2010
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.5M
139.3M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
JYNT
SCLX
Price
$8.79
$14.08
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$17.00
N/A
AVG Volume (30 Days)
96.2K
72.9K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$54,176,002.00
$40,360,000.00
Revenue This Year
$6.11
N/A
Revenue Next Year
$6.13
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
10.47
N/A
52 Week Low
$7.50
$3.60
52 Week High
$13.47
$34.27

Technical Indicators

Market Signals
Indicator
JYNT
SCLX
Relative Strength Index (RSI) 51.18 35.68
Support Level $8.64 $12.87
Resistance Level $8.99 $14.40
Average True Range (ATR) 0.27 0.94
MACD -0.01 -0.30
Stochastic Oscillator 52.74 18.92

Price Performance

Historical Comparison
JYNT
SCLX

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: